Swiss firm 4bases began clinical pilot studies in two Italian hospitals to validate a nanopore sequencing workflow, KaryoSolver, for real‑time detection of copy number variants (CNVs) against array‑CGH. The PromethIon‑based KaryoSolver shortens turnaround to roughly 24 hours and supports high multiplexing, positioning nanopore read‑count approaches as a faster alternative for diagnostic cytogenetics. The company aims to commercialize the end‑to‑end KaryoPrep and KaryoSolver software package after pilots complete this quarter.